title: Correlation of galectin-3/galectin-3-binding sites with low differentiation status in head and neck squamous cell carcinomas.
abstract: The accurate determination of levels of differentiation is of prognostic value in human head and neck squamous cell carcinomas (HNSCCs). Because the deliberate selection of biochemical determinants accompanying certain stages of differentiation can refine the predictive power of histochemical assessments, the application of the quantitative evaluation of staining distribution and intensity by computer-assisted microscopy is one prerequisite to potential improvements. We used 2 innovative approaches with peanut agglutinin based on encouraging results with respect to common lectin-histochemistry. First, we used a custom-made neoglycoprotein to monitor the presence of Thomsen-Friedenreich (T) antigen-binding sites. Second, we measured the presence of 2 galectins immunohistochemically and, at the same time, measured lectin-histochemically the presence of accessible ligands for the endogenous lectins. We also monitored the presence of calcyclin, a protein with relevance to cell cycle progression or exocytosis. With 61 cases of HNSCC as their basis, including 31 oral, 20 laryngeal, and 10 hypopharyngeal lesions, the data show that the main modifications observed in connection with a loss of differentiation are related to a modification in the levels of both galectin-3/galectin-3-binding site and T-antigen/T-antigen-binding site expressions. The data obtained also suggest that galectin-3 could act as an acceptor site for the T antigen. Because the level of differentiation is known to be indicative of the recurrence rate in HNSCCs and our data clearly indicate that galectin-3 and the T antigen (and their respective binding sites) are involved in dedifferentiation processes, further investigation is warranted into the roles of galectins in HNSCC tumor progression and recurrence analysis.
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery and Pathology, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Belgium.
authors.forename: S
authors.initials: S
authors.lastname: Delorge
authors.forename: S
authors.initials: S
authors.lastname: Saussez
authors.forename: P
authors.initials: P
authors.lastname: Pelc
authors.forename: B
authors.initials: B
authors.lastname: Devroede
authors.forename: H
authors.initials: H
authors.lastname: Marchant
authors.forename: M
authors.initials: M
authors.lastname: Burchert
authors.forename: F Y
authors.initials: FY
authors.lastname: Zeng
authors.forename: A
authors.initials: A
authors.lastname: Danguy
authors.forename: I
authors.initials: I
authors.lastname: Salmon
authors.forename: H J
authors.initials: HJ
authors.lastname: Gabius
authors.forename: R
authors.initials: R
authors.lastname: Kiss
authors.forename: S
authors.initials: S
authors.lastname: Hassid
mesh_terms: D000368:Aged; D000943:Antigens, Differentiation / Q000378:metabolism*; D001665:Binding Sites; D002294:Carcinoma, Squamous Cell / Q000378:metabolism*; D018797:Cell Cycle Proteins; D005260:Female; D037502:Galectin 3; D006258:Head and Neck Neoplasms / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D037102:Lectins / Q000378:metabolism; D008024:Ligands; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D011237:Predictive Value of Tests; D000075383:S100 Calcium Binding Protein A6; D009418:S100 Proteins / Q000378:metabolism
chemical_list: D000943:Antigens, Differentiation; D018797:Cell Cycle Proteins; D037502:Galectin 3; D037102:Lectins; D008024:Ligands; D000075383:S100 Calcium Binding Protein A6; D009418:S100 Proteins; C055351:S100A6 protein, human